Staburo Summer Party 2023

Staburo Summer Party 2023

Staburo Summer Party 2023

A few days ago the time had come for our Staburo summer party.

On a late Wednesday afternoon all Staburo employees including families met at the event location Rothof in Munich Bogenhausen.

The day started with mixed weather, but right at the start of our event it was dry, sunny and warm. 

There were many fun activities going on at our event area. Depending on individual preferences all guests had the possibility to play beach volleyball, table tennis, badminton, viking chess and much more. Naturally some fun competitions have been developed during the sports activities. For our youngest guests, the water pistols and water bombs were the most fun.

After some fun and active hours a large and very delicious barbecue buffet was served for everyone – of course including vegetarian options and some tasty dessert. A beach bar with various drinks and music is of course a must at a summer party and was provided at our event area.

As dusk fell, there were still colleagues who were active playing some of our games and other colleagues who enjoyed socializing around the fire bowl.

At the end we look back at a nice, fun and tasty summer party and are happy that so many employees and families joined. It was nice seeing everyone getting involved in different team combinations and connecting with other colleagues.

Data analysis, clinical biostatistics and more.

Staburo contributes to biomarker analysis for colorectal cancer phase 2 study

Staburo contributes to biomarker analysis for colorectal cancer phase 2 study

Staburo contributes to biomarker analysis for colorectal cancer phase 2 study

Staburo regularly contributes to publications in different areas.

Most recently, Staburo supported the analysis of a Phase II Study in patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC).

The study was the largest prospective study to date assessing the combination of anti-programmed cell death protein 1 (PD-1) antibodies and multikinase inhibitors. This combination has shown encouraging activity in several tumour types, including colorectal cancer. In this study, 5 of 70 treated patients had a partial response, corresponding to an objective response rate of 7%.

The safety profile was manageable and consistent with the known safety profiles of both treatments, except for a higher incidence of grade 3 rash in the study.

Staburo was involved in the biomarker analysis, where tumour samples from 40 patients were analysed by immunohistochemistry. One of the results was that higher expression of biomarkers for pre-existing immune sensitivity (e.g., PD-L1 or CD8) tended to lead to a better clinical outcome.

The paper was published in April 2023 in The Lancet: https://doi.org/10.1016/j.eclinm.2023.101917

Staburo’s contribution is mentioned in the acknowledgements – special thanks to our colleagues Laura Schlieker and Rebecca Freudling.

Data analysis, clinical biostatistics and more.